NDLI: A Rifapentine-Containing Inhaled Triple Antibiotic Formulation for Rapid Treatment of Tubercular Infection

Content Provider	Springer Nature Link
Author	Chan, John Gar Yan Tyne, Anneliese S. Pang, Angel Chan, Hak Kim Young, Paul M. Britton, Warwick J. Duke, Colin C. Traini, Daniela
Copyright Year	2013
Abstract	The potential for rifapentine-containing oral therapeutic regimens to significantly shorten the current six-month anti-tubercular treatment regimen is confounded by high plasma protein binding of rifapentine. Inhaled aerosol delivery of rifapentine, a more potent anti-tubercular antibiotic drug, in combination with other first-line antibiotics may overcome this limitation to deliver a high drug dose at the pulmonary site of infection.A formulation consisting of rifapentine, moxifloxacin and pyrazinamide, with and without leucine, was prepared by spray-drying. This formulation was assessed for its physico-chemical properties, in vitro aerosol performance and antimicrobial activity.The antibiotic powders, with and without leucine, had similar median aerodynamic diameters of 2.58 ± 0.08 μm and 2.51 ± 0.06 μm, with a relatively high fine particle fraction of 55.5 ± 1.9% and 63.6 ± 2.0%, respectively. Although the powders were mostly amorphous, some crystalline peaks associated with the δ polymorph for the spray-dried crystalline pyrazinamide were identified.Stabilisation of the powder with 10% w/w leucine and protection from moisture ingress was found to be necessary to prevent overt crystallisation of pyrazinamide after long-term storage. In vitro biological assays indicated antimicrobial activity was retained after spray-drying. Murine pharmacokinetic studies are currently underway.
Starting Page	1239
Ending Page	1253
Page Count	15
File Format	PDF
ISSN	07248741
Journal	Pharmaceutical Research
Volume Number	31
Issue Number	5
e-ISSN	1573904X
Language	English
Publisher	Springer US
Publisher Date	2013-11-16
Publisher Place	Boston
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	inhaled aerosol rifapentine treatment shortening tuberculosis Pharmacology/Toxicology Pharmacy Biochemistry Medical Law Biomedical Engineering
Content Type	Text
Resource Type	Article
Subject	Organic Chemistry Pharmacology Molecular Medicine Pharmacology (medical) Biotechnology Pharmaceutical Science

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis

Inhaled Drug Delivery for Tuberculosis Therapy

Iloprost-Containing Liposomes for Aerosol Application in Pulmonary Arterial Hypertension: Formulation Aspects and Stability

Single-dose Pharmacokinetics of Rifapentine in Elderly Men

Respirable PLGA Microspheres Containing Rifampicin for the Treatment of Tuberculosis: Manufacture and Characterization

Inhalable Microparticles Containing Drug Combinations to Target Alveolar Macrophages for Treatment of Pulmonary Tuberculosis

Respirable PLGA Microspheres Containing Rifampicin for the Treatment of Tuberculosis: Screening in An Infectious Disease Model

Investigation of a Degradant in a Biologics Formulation Buffer Containing L-Histidine

Electrospun Formulations Containing Crystalline Active Pharmaceutical Ingredients

A Rifapentine-Containing Inhaled Triple Antibiotic Formulation for Rapid Treatment of Tubercular Infection

Similar Documents

Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis

Inhaled Drug Delivery for Tuberculosis Therapy

Iloprost-Containing Liposomes for Aerosol Application in Pulmonary Arterial Hypertension: Formulation Aspects and Stability

Single-dose Pharmacokinetics of Rifapentine in Elderly Men

Respirable PLGA Microspheres Containing Rifampicin for the Treatment of Tuberculosis: Manufacture and Characterization

Inhalable Microparticles Containing Drug Combinations to Target Alveolar Macrophages for Treatment of Pulmonary Tuberculosis

Respirable PLGA Microspheres Containing Rifampicin for the Treatment of Tuberculosis: Screening in An Infectious Disease Model

Investigation of a Degradant in a Biologics Formulation Buffer Containing L-Histidine

Electrospun Formulations Containing Crystalline Active Pharmaceutical Ingredients

A Rifapentine-Containing Inhaled Triple Antibiotic Formulation for Rapid Treatment of Tubercular Infection